Generi Biotech

Executive Summary

Generi Biotech is a Czech biotechnology company specializing in the development, manufacturing, and sale of proprietary in-vitro diagnostic (IVD) kits, PCR reagents, and custom oligonucleotides. Founded in 2006 and headquartered in Hradec Králové, the company also offers contract research organization (CRO) services, including GLP/GMP testing for drug development. Despite its pre-clinical stage, Generi Biotech has established a solid foothold in the diagnostics market by addressing niche applications such as molecular diagnostics and custom nucleic acid synthesis. The company's product portfolio includes ready-to-use PCR kits and reagents for infectious disease detection, genetic testing, and research applications. By leveraging its expertise in oligonucleotide synthesis and PCR technology, Generi Biotech serves both academic and industrial clients across Europe and beyond. The company's private status and lack of disclosed funding rounds suggest a lean operational model focused on sustainable growth. Its ability to offer end-to-end solutions from custom synthesis to diagnostic kits positions it as a versatile player in the diagnostics space. However, given the lack of disclosed revenue or partnership data, the company's market traction remains uncertain. In summary, Generi Biotech represents a small but established diagnostics firm with potential for growth through product diversification and expansion into new geographic markets.

Upcoming Catalysts (preview)

• Q4 2026Launch of new PCR diagnostic kit for emerging infectious diseases60% success
• Q1 2027Strategic partnership or distribution agreement in Western Europe50% success
• Q2 2027Expansion of CRO services into new therapeutic areas (e.g., oncology or rare diseases)65% success